Создание системы пересмотра иммуногистохимических исследований при диагностике рака молочной железы
Общественное здоровье и организация здравоохранения
Леонтьев С.Л., Сазонов С.В.
УДК 616.428-018-091.8
ГБУЗ СО Центр оказания специализированных видов медицинской помощи населению «Институт медицинских клеточных технологий», г. Екатеринбург, Россия
Резюме.
Недостаток финансовых ресурсов может ограничивать набор методов, которые могут применяться в ближайшее время на разных уровнях диагностики рака молочной железы. До достижения максимального уровня методов диагностики патоморфологическая лаборатория, обеспечивая принцип доступности высокотехнологичных видов медицинской помощи, может являться звеном референс-системы, позволяющей поддерживать методический уровень исследования гистологического материала на оптимально достаточном уровне.
Ключевые слова:
организация референс-исследований, иммуногистохимические исследования, рак молочной железы, стратификация методов исследования, контроль качества исследований.
ЛИТЕРАТУРА
1. Криволапов Ю.А., Пешков М.В., Леенман Е.Е. и др. Первый опыт проведения внешнего контроля качества иммуногистохимических исследований в диагностике лимфопролиферативных заболеваний// Архив патологии, 2011. – Том 73, №2. – С. 25-32.
2. Франк Г.А., Мальков П.Г., Мещерякова Н.Г. Контроль качества морфологической диагностики опухолей по результатам школы патоморфологии портала Oncology.ru// Архив патологии, 2011. – Том 73, №2. – С. 32-35.
3. Allred D., Harvey H.M., Berardo M.D., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis//Mod. Pathol., 1998 – N11 – P.155–168.
4. Anderson B.O., Yip C.H., Ramsey S.D., et al. Breast cancer in limited-resource countries: health care systems and public policy// Breast J. – 2006, N12 (suppl. 1) – P. 54–69.
5. Anderson B.O., Shyyan R., Eniu A.E., et al. Breast cancer in limitedresource countries: an overview of the Breast Health Global Initiative 2005 guidelines // Breast J. 2006 — N12 (suppl. 1) – P. 3-26.
6. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases // Cancer, 1989 – N 63 — P. 181–187.
7. Chaiwun B., Settakorn J., Ya-In C., Wisedmongkol W., Rangdaeng S., Thorner P. Effectiveness of fine-needle aspiration cytology of the breast: analysis of 2,375 cases from northern Thailand// Diagn. Cytopathol. — 2002, N26 – P. 201–205.
8. Eniu AE, Carlson RW, Aziz Z, et al. Breast cancer in limitedresource countries: treatment and allocation of resources// Breast J. – 2006, N 12 (suppl. 1) — P. 38–53.
9. Hoda S.A., Rosen P.P. Practical considerations in the pathologic diagnosis of needle core biopsies of breast// Am. J. Clin. Pathol. — 2002, N 118, P. 101–108.
10. Green F., Page D., Fleming I., et al., AJCC Cancer Staging Manual, 6 th ed. New York: Springer, — 2002, N 2 — P. 221–240.
11. Lannin D.R., Silverman J.F., Walker C., Pories W.J. Costeffectiveness of fine needle biopsy of the breast// Ann. Surg. – 1986, N 203 – P. 474-480.
12. Logan-Young W., Dawson A.E., Wilbur D.C., et al. The costeffectiveness of fine-needle aspiration cytology and 14-gauge core needle biopsy compared with open surgical biopsy in the diagnosis of breast carcinoma// Cancer, 1998 — N 82, P. 1867–1873.
13. Masood S. The expanding role of pathologists in the diagnosis and management of breast cancer: worldwide excellence in breast pathology program// Breast J., 2003 – N. 9(suppl. 2)- P. 94–97.
14. Meunier M., Clough K. Fine needle aspiration cytology versus percutaneous biopsy of nonpalpable breast lesions// Eur. J. Radiol. 2002, — N 42 – P. 10–16.
15. Quiet C.A., Ferguson D.J., Weichselbaum R.R., Hellman S. Natural history of node positive breast cancer: the curability of small cancers with a limited number of positive nodes// J. Clin. Oncol., 1996 – N. 14 – P. 3105–3111.
16. Page D.L., Jensen R.A., Simpson J.F. Routinely available indicators of prognosis in breast cancer// Br. Cancer Res. Treat., 1998 — N51 – P. 195–208.
17. Pinder S., Ellis I.O., O’Rourke S., et al. Pathological prognostic factors in breast cancer. Vascular invasion: relationship with recurrence and survival in a large series with long-term follow-up// Histopathology, 1994 – N 24 – P. 41–47.
18. Pisano E.D., Fajardo L.L., Caudry D.J., et al. Fine-needle aspiration biopsy of nonpalpable breast lesions in a multicenter clinical trial: results from the Radiologic Diagnostic Oncology Group V // Radiology, 2001 — V. 219 – P. 785–792.
19. Sobin L.H., Wittekind C., eds. TNM Classification of Malignant Tumours, 6th ed. New York: John Wiley & Sons, 2002.
20. Terry J., Torlakovic E.E., Garratt J. et al. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/ Immunohistochemistry// Appl. Immunohistochem. Mol. Morphol. – 2009. – Vol. 17. – P. 375-382.
21. Vargas H.I., Anderson B.O., Chopra R., et al. Diagnosis of breast cancer in countries with limited resources// Breast J., 2003 – N 9 (suppl. 2) – P. 60–66.
22. Vargas H.I., Masood S. Implementation of a minimally invasive breast biopsy program in 30 countries with limited resources// Breast J., 2003 – N 9 (suppl.2) – P. 81–85.
23. Vargas H.I., Vargas M.P., Gonzalez K.D., et al. Diagnosis of palpable breast masses: ultrasound-guided large core biopsy in a multidisciplinary setting// Am. Surg., 2004 — V. 70 – P. 867–871.
24. Veronese S.M., Gambacorta M., Gottardi O., et al. Proliferation index as a prognostic marker in breast cancer// Cancer, 1993 — V. 71 – P. 3926–3931.
25. Vyberg M., Torlakovic E., Seidal T. et al. Nordic immunohistochemical quality control// Croat. Med. J. – 2005. – Vol. 46. – P.368-371.
26. World Health Organization. Executive summary. In: National Cancer Control Programmes: Policies and Managerial Guidelines. Geneva. Switzerland: World Health Organization, 2002:i–xxiv.
27. Wolff A.C., Hammond M.E., Schwartz J.N. et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendation for human epidermal growth factor receptor 2 testing in breast cancer// Arch. Pathol. Lab. Med. – 2007. – Vol.131. – P.18-43.
1. Криволапов Ю.А., Пешков М.В., Леенман Е.Е. и др. Первый опыт проведения внешнего контроля качества иммуногистохимических исследований в диагностике лимфопролиферативных заболеваний// Архив патологии, 2011. – Том 73, №2. – С. 25-32.
2. Франк Г.А., Мальков П.Г., Мещерякова Н.Г. Контроль качества морфологической диагностики опухолей по результатам школы патоморфологии портала Oncology.ru// Архив патологии, 2011. – Том 73, №2. – С. 32-35.
3. Allred D., Harvey H.M., Berardo M.D., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis//Mod. Pathol., 1998 – N11 – P.155–168.
4. Anderson B.O., Yip C.H., Ramsey S.D., et al. Breast cancer in limited-resource countries: health care systems and public policy// Breast J. – 2006, N12 (suppl. 1) – P. 54–69.
5. Anderson B.O., Shyyan R., Eniu A.E., et al. Breast cancer in limitedresource countries: an overview of the Breast Health Global Initiative 2005 guidelines // Breast J. 2006 — N12 (suppl. 1) – P. 3-26.
6. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases // Cancer, 1989 – N 63 — P. 181–187.
7. Chaiwun B., Settakorn J., Ya-In C., Wisedmongkol W., Rangdaeng S., Thorner P. Effectiveness of fine-needle aspiration cytology of the breast: analysis of 2,375 cases from northern Thailand// Diagn. Cytopathol. — 2002, N26 – P. 201–205.
8. Eniu AE, Carlson RW, Aziz Z, et al. Breast cancer in limitedresource countries: treatment and allocation of resources// Breast J. – 2006, N 12 (suppl. 1) — P. 38–53.
9. Hoda S.A., Rosen P.P. Practical considerations in the pathologic diagnosis of needle core biopsies of breast// Am. J. Clin. Pathol. — 2002, N 118, P. 101–108.
10. Green F., Page D., Fleming I., et al., AJCC Cancer Staging Manual, 6 th ed. New York: Springer, — 2002, N 2 — P. 221–240.
11. Lannin D.R., Silverman J.F., Walker C., Pories W.J. Costeffectiveness of fine needle biopsy of the breast// Ann. Surg. – 1986, N 203 – P. 474-480.
12. Logan-Young W., Dawson A.E., Wilbur D.C., et al. The costeffectiveness of fine-needle aspiration cytology and 14-gauge core needle biopsy compared with open surgical biopsy in the diagnosis of breast carcinoma// Cancer, 1998 — N 82, P. 1867–1873.
13. Masood S. The expanding role of pathologists in the diagnosis and management of breast cancer: worldwide excellence in breast pathology program// Breast J., 2003 – N. 9(suppl. 2)- P. 94–97.
14. Meunier M., Clough K. Fine needle aspiration cytology versus percutaneous biopsy of nonpalpable breast lesions// Eur. J. Radiol. 2002, — N 42 – P. 10–16.
15. Quiet C.A., Ferguson D.J., Weichselbaum R.R., Hellman S. Natural history of node positive breast cancer: the curability of small cancers with a limited number of positive nodes// J. Clin. Oncol., 1996 – N. 14 – P. 3105–3111.
16. Page D.L., Jensen R.A., Simpson J.F. Routinely available indicators of prognosis in breast cancer// Br. Cancer Res. Treat., 1998 — N51 – P. 195–208.
17. Pinder S., Ellis I.O., O’Rourke S., et al. Pathological prognostic factors in breast cancer. Vascular invasion: relationship with recurrence and survival in a large series with long-term follow-up// Histopathology, 1994 – N 24 – P. 41–47.
18. Pisano E.D., Fajardo L.L., Caudry D.J., et al. Fine-needle aspiration biopsy of nonpalpable breast lesions in a multicenter clinical trial: results from the Radiologic Diagnostic Oncology Group V // Radiology, 2001 — V. 219 – P. 785–792.
19. Sobin L.H., Wittekind C., eds. TNM Classification of Malignant Tumours, 6th ed. New York: John Wiley & Sons, 2002.
20. Terry J., Torlakovic E.E., Garratt J. et al. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/ Immunohistochemistry// Appl. Immunohistochem. Mol. Morphol. – 2009. – Vol. 17. – P. 375-382.
21. Vargas H.I., Anderson B.O., Chopra R., et al. Diagnosis of breast cancer in countries with limited resources// Breast J., 2003 – N 9 (suppl. 2) – P. 60–66.
22. Vargas H.I., Masood S. Implementation of a minimally invasive breast biopsy program in 30 countries with limited resources// Breast J., 2003 – N 9 (suppl.2) – P. 81–85.
23. Vargas H.I., Vargas M.P., Gonzalez K.D., et al. Diagnosis of palpable breast masses: ultrasound-guided large core biopsy in a multidisciplinary setting// Am. Surg., 2004 — V. 70 – P. 867–871.
24. Veronese S.M., Gambacorta M., Gottardi O., et al. Proliferation index as a prognostic marker in breast cancer// Cancer, 1993 — V. 71 – P. 3926–3931.
25. Vyberg M., Torlakovic E., Seidal T. et al. Nordic immunohistochemical quality control// Croat. Med. J. – 2005. – Vol. 46. – P.368-371.
26. World Health Organization. Executive summary. In: National Cancer Control Programmes: Policies and Managerial Guidelines. Geneva. Switzerland: World Health Organization, 2002:i–xxiv.
27. Wolff A.C., Hammond M.E., Schwartz J.N. et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendation for human epidermal growth factor receptor 2 testing in breast cancer// Arch. Pathol. Lab. Med. – 2007. – Vol.131. – P.18-43.
Авторская справка:
Леонтьев Сергей Леопольдович
Сазонов Сергей Владимирович
ГБУЗ СО Центр оказания специализированных видов медицинской помощи населению «Институт медицинских клеточных технологий»
Россия, 620036, г. Екатеринбург, ул. Соболева, 25
e-mail: Prof-SSazonov@yandex.ru